Promaxo
PrivateLast Round
Early Stage
VC
Mar 30, 2026
Est. Valuation
$226.9M
Total Funding Raised
$97.75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Promaxo is a medical technology company that develops and commercializes portable, point-of-care MRI systems integrated with AI and robotics for prostate cancer diagnosis and treatment.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Medical Imaging, Medical AI
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Promaxo Comparables
Compare Promaxo with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Chipiron | 84% | |
| Hyperfine | 82% | |
| Exact Imaging | 75% |
Promaxo Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Stage VC | Mar 30, 2026 | ||||
| Series B Extension | Jul 10, 2024 | ||||
| Early Funding | Mar 25, 2024 | ||||
| Strategic | Oct 4, 2023 | ||||
| Series B Extension | Apr 7, 2022 | ||||
Series B Extension | Jan 13, 2021 |
Key People
Founding team and executive leadership
Promaxo Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Keiretsu Forum | Series B Extension |
| Spark Growth Ventures | Series B Extension |
| iO Life Ventures | Series B Extension |
| Kineticos Ventures | Series B Extension |
| Zynext Ventures | Series B Extension, Early Funding |
| K2X Capital | Series B Extension |
| Almond Tree Capital | Series A, Series B, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 30, 2026
$27M raised in early stage venture capital round.
- Mar 1, 2026
Compact MRI platform cleared for office-based and outpatient procedures.
Recent news
Latest coverage and updates
- is_developingOct 22, 2026
Promaxo is developing a minimally-invasive and patient-centric MRI and robotic platform to improve the precision and speed of diagnosis and interventions.
- receives_financingOct 22, 2026
Promaxo announces the initial close of its Series C financing with New Science Ventures and Amara Ventures and closes a $100M credit facility in California on Oct 22nd '26 to expand manufacturing capacity, reduce backlog, and support new regulatory filings.
Promaxo Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Promaxo's valuation, stock price, and market status.
Is Promaxo a public or private company?
Promaxo is a private company.
What is the current stock price of Promaxo?
Promaxo is a private company, so its shares have no public market price. Caplight tracks Promaxo's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Promaxo worth (valuation)?
Promaxo's valuation is estimated at $226.9M based on funding round data.
Can I buy Promaxo stock?
Promaxo shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Promaxo's last funding round?
Promaxo's most recent funding round was Early Stage VC on March 30, 2026.
Who are the main investors in Promaxo?
Key investors in Promaxo include Kineticos Ventures, Huami Corp.
Will Promaxo IPO soon?
No public IPO plans have been announced for Promaxo.
How can I track Promaxo secondary market activity?
Caplight tracks bids, offers, and trades in Promaxo's shares on secondary markets.